Harmony Biosciences Holdings (HRMY) Receivables (2019 - 2026)

Harmony Biosciences Holdings has disclosed Receivables across 8 years of filings, most recently posting $108.2 million for Q1 2026.

• Receivables for Q1 2026 came in at $108.2 million, up 2.13% year-over-year; the trailing twelve-month figure through Mar 2026 was $108.2 million (up 2.13% YoY), and the FY2025 annual result was $96.8 million, up 16.56% from the prior year.
• Receivables came in at $108.2 million for Q1 2026 at Harmony Biosciences Holdings, up from $96.8 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $108.2 million in Q1 2026 to a low of $38.1 million in Q1 2022.
• The 5-year median for Receivables is $79.7 million (2024), against an average of $75.7 million.
• Across the five-year window, Receivables surged 65.83% in 2022 and grew 2.13% in 2026, its largest moves.
• Harmony Biosciences Holdings' Receivables stood at $54.7 million in 2022, then soared by 35.44% to $74.1 million in 2023, then increased by 11.99% to $83.0 million in 2024, then gained by 16.56% to $96.8 million in 2025, then gained by 11.81% to $108.2 million in 2026.
• The last three Receivables figures came in at $108.2 million (Q1 2026), $96.8 million (Q4 2025), and $100.7 million (Q3 2025), per Business Quant data.